Adjuvant Therapy
Adjuvant therapy refers to additional treatment given after the primary treatment for cancer, aimed at lowering the risk of the cancer coming back. It is commonly used when there is a high risk of micrometastasis or residual disease despite successful primary intervention (e.g., surgery).
Key Modalities
- Chemotherapy: Systemic treatment to kill rapidly dividing cells.
- Radiation Therapy: Localized treatment to destroy remaining cancer cells.
- Immunotherapy: Enhances the body’s immune system to fight cancer.
- Hormone Therapy: Used for hormone-sensitive cancers (e.g., breast, prostate).
- Targeted Therapy: Attacks specific abnormalities in cancer cells.
Recent Developments in Melanoma
Significant advancements in immunotherapy and personalized-medicine have reshaped adjuvant strategies for high-risk melanoma.
- mRNA Vaccine Integration: Personalized mRNA vaccines are being investigated to stimulate a robust immune response against tumor-specific neoantigens.
- Moderna & Merck Collaboration: Recent Phase 3 trial results for the combination of the personalized mRNA vaccine (Intismeran Autogene) and Keytruda (pembrolizumab) in resected melanoma have shown positive outcomes.
- Clinical Impact: This combination represents a potential shift from standard-of-care immunotherapy alone to a dual-modality approach leveraging both checkpoint inhibition and personalized antigen presentation.
- Source Analysis: Detailed breakdown of the clinical significance and trial data is available in Moderna Merck mRNA Cancer Vaccine and Keytruda for Resected Melanoma Adjuvant Therapy.